19-Jan-2023 | Facts and Factors
According to Facts and Factors, the global pneumococcal vaccine market size was worth around USD 8.57 billion in 2021 and is predicted to grow to around USD 12 billion by 2030 with a compound annual growth rate (CAGR) of roughly 5.34% between 2022 and 2030.
Vaccines that protect humans against pneumococcal diseases are known as pneumococcal vaccines. The diseases are caused due to Streptococcus pneumonia, a type of bacteria. Pneumococcal vaccines can prevent conditions like sepsis, meningitis, and pneumonia. There are two basic types of vaccines; namely polysaccharides vaccines and conjugate vaccines. The medication is given by injecting them just under the skin or into the muscle. The World Health Organization (WHO) recommends that children and infants should be given conjugate vaccines during routine immunization.
Browse the full “Pneumococcal Vaccine Market Size, Share, Growth Analysis Report By Sector (Public and Private), By Vaccine Type (Pneumococcal Polysaccharide Vaccine and Pneumococcal Conjugate Vaccine), By Distribution Channel (Non-Government Organizations, Distribution Partner Companies, and Government Authorities), By Product Type (Pneumovax 23, Synflorix, and Prevnar 13), and By Region - Global and Regional Industry Insights, Overview, Comprehensive Analysis, Trends, Statistical Research, Market Intelligence, Historical Data and Forecast 2022 – 2030" report at https://www.fnfresearch.com/pneumococcal-vaccine-market
The recommended doses are known to be preventive at least 71% to 93% of the time. The vaccines are generally considered as safe apart from mild discomfort seen in some situations. The first vaccine ever developed to treat pneumococcal conditions was in 1980 and it currently holds a place in the World Health Organization’s list of essential medicines. The Pneumococcal Vaccines Accelerated Development and Introduction Plan (PneumoADIP) program is run across the globe to accelerate the accessibility and evaluation of the situations surrounding vaccines in developing countries.
The global pneumococcal vaccine market is projected to grow owing to the increase in research and development (R&D) of new medicines as well as growing initiatives are undertaken by various regional, international, public, and private sector bodies to educate the population about pneumococcal diseases and preventive measures. Various countries run year-long programs under which infants and children are administered the pneumococcal vaccine free of cost falling the regional immunization programs. For instance, people above the age group of 65 years are eligible for free vaccination as mentioned by the Pneumonia Vaccination Service.
The global market may grow further due to the growing cases of meningitis. It is a serious condition that is triggered when bacteria attack the membranes covering the spinal cord and brain. The WHO mentions it to be a devastating disease and a major public health concern. It can spread through close contact with an infected person. More than 2.49 million cases of meningitis are recorded every year; it leads to over 24,000 deaths annually.
The global market faces restraints owing to various factors. Pneumococcal vaccines have proven to be effective in immunizing the population against the diseases but some of the areas of concern remain unsolved. The issues under consideration include the exact and optimum vaccine formulation along with the accurate schedule for every setting required to administer the vaccine. In developed economies, infant pneumococcal vaccine drives have helped to build herd immunity; however, the duration of the protection provided by the vaccines remains unclear.
The growing elderly population may provide growth opportunities however the high cost of branded vaccines could challenge the market expansion.
Segmental Overview
The global pneumococcal vaccine market is segmented based on sector, vaccine type, distribution channel, product type, and region
Based on the vaccine type, the global market segments are pneumococcal polysaccharide vaccine and pneumococcal conjugate vaccine. In 2021, the highest growth was registered by the pneumococcal conjugate vaccine segment due to higher Food and Drugs Administration (FDA) approvals further encouraged by recommendations by medical professionals comparing the effect of both types of vaccines. The medication is to be administered in infants and helps to enhance the immunization level in children that are 6 weeks old to 5 years of age. Doctors recommend the vaccine type for both children and adults leading to a higher consumer database.
Based on product type, the global market divisions are Pneumovax 23, Synflorix, and Prevnar 13. In 2021, the fastest-growing segment was the Prevnar 13 segment and the same trend is expected during the forecast period. It is one of the most recommended vaccination types by the WHO and most countries use Prevnar 13 during national-level immunization drives. It is recommended for adults who are above the age of 50 years.
Regional Overview
North America is projected to lead the global pneumococcal vaccine market due to the high innovation and product launch rate. The regional population health and safety-related bodies have initiated various programs to encourage mass pneumococcal vaccine drives which is the major reason why most of the developed economies have almost developed herd immunity against the diseases. The number of approvals for vaccines to prevent the spread of pneumococcal diseases has increased tremendously.
In October 2021, Advisory Committee on Immunization Practices (ACIP) by the Centers for Disease Control and Prevention (CDC) provided an updated recommendation list for the vaccine administration in adults. As per the new list, every individual above the age of 65 years is mandated to take a pneumococcal conjugate vaccine. The available options are PCV20 and PCV15. The recommendation also mandates every individual between 19 years to 64 years who has certain medical conditions to administer a vaccine providing protection against pneumococcal diseases.
Report Scope
Report Attribute |
Details |
Market Size in 2021 |
USD 8.57 Billion |
Projected Market Size in 2030 |
USD 12 Billion |
CAGR Growth Rate |
5.34% CAGR |
Base Year |
2021 |
Forecast Years |
2022-2030 |
Key Market Players |
Merck & Co. Inc., Astellas Pharma Inc., Walvax Biotechnology Co. Ltd., Panacea Biotec Ltd., GlaxoSmithKline Plc., Serum Institute of India Pvt Ltd, Sanofi, Pfizer Inc. , and others. |
Key Segment |
By Sector, Vaccine Type, Distribution Channel, Product Type, and Region |
Major Regions Covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East &, Africa |
Purchase Options |
Request customized purchase options to meet your research needs. Explore purchase options |
Competitive Analysis
Merck & Co. Inc., Astellas Pharma Inc., Walvax Biotechnology Co. Ltd., Panacea Biotec Ltd., GlaxoSmithKline Plc., Serum Institute of India Pvt Ltd, Sanofi, and Pfizer Inc. are the leading players in the global pneumococcal vaccine market.
Recent Developments:
- In June 2022, the US FDA approved the use of VAXNEUVANCE developed by Merck to prevent the spread of pneumococcal diseases in children and infants. The new vaccine is a 15-valent conjugate vaccine
- In December 2020, India witnessed the launch of its first indigenous pneumococcal vaccine developed by Vardhan
The global pneumococcal vaccine market is segmented as follows:
By Sector
By Vaccine Type
- Pneumococcal Polysaccharide Vaccine
- Pneumococcal Conjugate Vaccine
By Distribution Channel
- Non-Government Organizations
- Distribution Partner Companies
- Government Authorities
By Product
- Pneumovax 23
- Synflorix
- Prevnar 13
By Region
- North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- South Africa
- Rest of the Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
About Us:
Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.
Contact Us:
Facts & Factors
A 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1 (347) 690-0211
Email: [email protected]
Web: https://www.fnfresearch.com
